One thing that hasn’t changed since 2017 is the strong defense of Medicaid from Democrats, hospital executives, and consumer ...

The FDA has approved Welireg (belzutifan) for the treatment of patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma.

The risk of recurrence was generally low among cervical cancer patients with no high-risk factors who underwent radical surgery without adjuvant therapy.

The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.